Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Aura Biosciences Inc ( (AURA) ) just unveiled an update.
On May 15, 2025, Aura Biosciences, Inc. entered into an underwriting agreement for a public offering of common stock and warrants, raising approximately $69.9 million. The proceeds are intended to fund clinical programs and operational expenses into the first half of 2027, potentially strengthening the company’s position in the oncology market by advancing treatments for ocular and urologic cancers.
The most recent analyst rating on (AURA) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on Aura Biosciences Inc stock, see the AURA Stock Forecast page.
Spark’s Take on AURA Stock
According to Spark, TipRanks’ AI Analyst, AURA is a Neutral.
Aura Biosciences’ overall stock score reflects its early-stage biotech profile, characterized by no revenue, increasing losses, and negative cash flows. While the company maintains a solid balance sheet, its stock faces bearish technical indicators and speculative valuation. The recent board appointment is a positive development, but the company’s financial health and market trends remain the primary concerns.
To see Spark’s full report on AURA stock, click here.
More about Aura Biosciences Inc
Aura Biosciences, Inc. operates in the biotechnology industry, focusing on developing innovative treatments for cancer, particularly in ocular and urologic oncology. The company’s primary products include virus-like drug conjugates (VDCs) designed to target and treat early-stage cancers, with a market focus on conditions such as choroidal melanoma and non-muscle invasive bladder cancer.
Average Trading Volume: 277,938
Technical Sentiment Signal: Sell
Current Market Cap: $246.3M
See more data about AURA stock on TipRanks’ Stock Analysis page.